Suppliers and packagers for generic pharmaceutical drug: LORLATINIB

LORLATINIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0227-01	30 TABLET, FILM COATED in 1 BOTTLE (0069-0227-01)	2018-11-19
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0227-03	120 TABLET, FILM COATED in 1 BOTTLE (0069-0227-03)	2018-11-19
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0231-01	30 TABLET, FILM COATED in 1 BOTTLE (0069-0231-01)	2018-11-19
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868	NDA	U.S. Pharmaceuticals	63539-927-01	30 TABLET, FILM COATED in 1 BOTTLE (63539-927-01)	2023-01-03

LORLATINIB SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report details the current supply chain landscape for lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor. The analysis focuses on key suppliers for active pharmaceutical ingredients (APIs) and critical intermediates, their geographical distribution, and potential supply chain risks.

What is Lorlatinib and What is Its Market Application?

Lorlatinib, marketed under the brand name Lorbrena in the United States and Lorviqua in Europe, is a targeted therapy approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after other ALK inhibitors and chemotherapy. It is also indicated for patients with brain metastases.

The drug functions by inhibiting ALK and ROS1 tyrosine kinases, which are often aberrantly activated in NSCLC, leading to tumor cell proliferation and survival. Lorlatinib's ability to penetrate the blood-brain barrier is a significant differentiator, making it effective against central nervous system metastases.

The global market for ALK inhibitors is projected to grow, driven by increasing NSCLC incidence and advancements in precision medicine. Lorlatinib's efficacy against specific mutations and its brain penetrative properties position it as a key therapeutic option in this segment.

Who are the Primary API and Intermediate Suppliers for Lorlatinib?

The synthesis of lorlatinib is a complex multi-step process. While specific proprietary supply chains are closely guarded by the innovator company, Pfizer, publicly available patent literature and industry databases provide insight into potential and established suppliers of key raw materials and intermediates.

Key Chemical Building Blocks and Their Potential Sources

The synthesis typically involves several advanced intermediates. Based on common synthetic routes described in patent literature, these include:

• 2,4-Dichloro-5-nitropyrimidine: This is a foundational pyrimidine derivative. Potential manufacturers of such halogenated and nitrated heterocycles are often found in China and India, regions with established fine chemical manufacturing capabilities.
• 4-(4-Chlorophenyl)piperidine-1-carboxylic acid tert-butyl ester: This intermediate incorporates a substituted piperidine ring. Companies specializing in heterocyclic chemistry and custom synthesis are likely involved.
• 2-Amino-5-bromo-3-methylpyridine: A substituted aminopyridine. Specialized pyridine derivative manufacturers would be the primary sources.
• Trifluoromethyl-substituted phenyl intermediates: These are crucial for the drug's pharmacodynamic properties. Many custom synthesis and specialty chemical companies globally can produce these.

Known or Probable API Manufacturers

The final API synthesis is typically performed by the innovator company or their designated Contract Development and Manufacturing Organizations (CDMOs). Given the complexity and intellectual property involved, specific CDMOs are rarely disclosed publicly for patented drugs in their initial market phases. However, large-scale API manufacturers with capabilities in complex organic synthesis and stringent Good Manufacturing Practice (GMP) compliance are essential.

Based on general industry trends for high-value APIs:

• Innovator Manufacturing: Pfizer likely maintains significant internal manufacturing capacity for lorlatinib API or has exclusive agreements with a limited number of highly vetted CDMOs.
• Potential CDMOs: Companies with extensive experience in multi-step API synthesis, including those in Europe (e.g., Switzerland, Germany) and North America, alongside established players in India and China that have demonstrated high-quality GMP compliance for complex molecules, are likely candidates. Examples of companies with such broad capabilities include Lonza, Catalent, and various large Indian pharmaceutical chemical manufacturers.

What is the Geographical Distribution of Lorlatinib's Supply Chain?

The geographical distribution of lorlatinib's supply chain reflects a globalized network of chemical manufacturing, with a concentration in specific regions for different types of precursors.

Regional Strengths in Pharmaceutical Chemical Manufacturing

• China: Dominant in the production of basic chemical reagents, common intermediates, and some advanced intermediates. Its large-scale manufacturing capacity and cost-effectiveness make it a primary source for many chemical building blocks.
• India: A major hub for API manufacturing and intermediate synthesis, particularly for generic drugs and established molecules. Indian companies possess strong expertise in complex organic synthesis and operate under strict regulatory oversight (e.g., FDA, EMA approved facilities).
• Europe (e.g., Germany, Switzerland): Known for high-purity specialty chemicals, custom synthesis of complex intermediates, and innovator API manufacturing. These regions emphasize quality, advanced technology, and robust intellectual property protection.
• United States: Houses advanced chemical synthesis capabilities and is a significant location for innovator R&D and manufacturing, as well as specialized intermediate production.

Lorlatinib-Specific Distribution Patterns

While specific lorlatinib intermediates' origins are proprietary, the general pattern suggests:

• Early-stage intermediates: Likely sourced from large-scale chemical manufacturers in China and India.
• Advanced intermediates: May originate from specialized manufacturers in India, China, or Europe, depending on the complexity and proprietary nature of the synthesis step.
• Final API synthesis: Primarily conducted within Pfizer's facilities or by closely controlled CDMOs, potentially located in North America or Europe to maintain quality control and intellectual property security.

What are the Potential Supply Chain Risks for Lorlatinib?

The complex, multi-step synthesis of lorlatinib, combined with its global sourcing, presents several potential supply chain risks that could impact availability and cost.

Geopolitical and Trade Policy Risks

• Trade Disputes and Tariffs: Tariffs or trade restrictions between major manufacturing regions (e.g., US-China, EU-China) can increase raw material costs and lead times.
• Regulatory Changes: Evolving environmental regulations in China or India can lead to temporary plant shutdowns or increased compliance costs, impacting production volumes.
• National Security and Supply Chain Resilience: Governments may increasingly favor domestic or allied sourcing for critical medicines, potentially disrupting established supply chains.

Manufacturing and Quality Control Risks

• Single-Source Dependency: Reliance on a single supplier for a critical intermediate creates vulnerability to production issues, quality failures, or supplier bankruptcy.
• GMP Non-Compliance: A quality lapse at any stage of the manufacturing process, particularly at an API or critical intermediate supplier, can lead to batch rejection, recalls, and significant delays.
• Process Deviations: Unforeseen issues in complex synthetic routes can lead to reduced yields, higher impurity profiles, or entirely failed batches, necessitating reprocessing or re-sourcing.
• Capacity Constraints: Increased demand or unexpected production disruptions at key suppliers can lead to shortages.

Logistics and Transportation Risks

• Global Shipping Disruptions: Port congestion, shipping container shortages, and increased freight costs, as seen in recent years, can delay deliveries and inflate costs.
• Lead Time Volatility: The extended lead times for specialized chemical manufacturing and global shipping make the supply chain susceptible to disruptions.
• Perishable or Sensitive Materials: Some intermediates may have specific storage and handling requirements, increasing logistical complexity and risk.

Intellectual Property and Security Risks

• Counterfeit Products: The high value of patented pharmaceuticals makes them targets for counterfeiting. Ensuring the integrity of the entire supply chain is critical.
• Data Security: Protection of proprietary synthetic routes and process information is paramount for innovator companies.

Environmental, Social, and Governance (ESG) Risks

• Environmental Incidents: Accidental releases or non-compliance with environmental regulations at manufacturing sites can lead to shutdowns and reputational damage.
• Labor Practices: Scrutiny of labor conditions at manufacturing facilities, especially in regions with less stringent labor laws, can lead to ethical concerns and supply chain disruptions.

What are the Regulatory Considerations for Lorlatinib Suppliers?

The regulatory landscape for pharmaceutical suppliers is stringent, focusing on quality, safety, and efficacy. For lorlatinib, adherence to these regulations is critical at all stages of the supply chain, from raw material sourcing to API manufacturing.

Good Manufacturing Practice (GMP)

• Core Requirement: All manufacturers of the lorlatinib API and critical intermediates must adhere to GMP standards as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
• Audits and Inspections: Facilities are subject to regular inspections by regulatory authorities and by the purchasing pharmaceutical company to ensure compliance.
• Quality Management Systems: Robust quality management systems are required, encompassing documented procedures, change control, deviation management, and personnel training.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

• DMFs (U.S.): API manufacturers often submit Drug Master Files to the FDA. These confidential documents contain detailed information about the manufacturing process, facility, and quality controls. Pharmaceutical companies referencing these DMFs in their drug applications can streamline the review process.
• CEPs (Europe): Manufacturers can obtain a Certificate of Suitability to the European Pharmacopoeia monographs from the European Directorate for the Quality of Medicines & HealthCare (EDQM). This demonstrates that the API complies with the relevant European Pharmacopoeia monograph and provides a high level of assurance for quality.

Traceability and Supply Chain Integrity

• Serialization and Track-and-Trace: Regulations like the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) require robust systems for tracking pharmaceutical products throughout the supply chain. While primarily focused on finished products, the principles of traceability are extending to API and intermediate sourcing.
• Supplier Qualification: Pharmaceutical companies must have rigorous programs for qualifying and monitoring their suppliers to ensure they meet all regulatory and quality requirements.

Environmental and Safety Regulations

• Chemical Handling and Disposal: Suppliers must comply with local and international regulations regarding the safe handling, storage, and disposal of hazardous chemicals used in synthesis.
• Worker Safety: Compliance with occupational health and safety regulations is mandatory for all manufacturing sites.

Key Takeaways

• Lorlatinib's supply chain involves complex organic synthesis with a global network of intermediate suppliers, predominantly in China, India, and Europe.
• The innovator company, Pfizer, likely controls the final API manufacturing through internal facilities or exclusive CDMO agreements.
• Key risks include geopolitical instability, trade disputes, manufacturing quality lapses, capacity constraints, and logistical disruptions.
• Strict adherence to GMP, robust quality management systems, and appropriate regulatory filings (e.g., DMFs, CEPs) are mandatory for all suppliers.
• Traceability and supplier qualification are critical to mitigating risks and ensuring the integrity of the lorlatinib supply chain.

Frequently Asked Questions

1. What are the main challenges in sourcing intermediates for lorlatinib? The primary challenges include the complexity of multi-step organic synthesis, ensuring consistent high quality and purity from global suppliers, and navigating potential geopolitical and trade-related disruptions.

2. How does Pfizer ensure the quality of its lorlatinib API and intermediates? Pfizer employs rigorous supplier qualification processes, conducts regular audits of manufacturing facilities, and mandates adherence to strict Good Manufacturing Practice (GMP) standards. They also likely have internal quality control testing at multiple stages of the supply chain.

3. Are there any publicly available lists of lorlatinib intermediate suppliers? No, specific lists of intermediate suppliers for patented drugs like lorlatinib are generally proprietary and not publicly disclosed by the innovator company to protect their supply chain strategy and intellectual property.

4. What impact does the blood-brain barrier penetration of lorlatinib have on its supply chain? The requirement for high purity and specific molecular characteristics to ensure efficacy, including blood-brain barrier penetration, places a higher demand on the precision and quality control of the API and its key intermediates. This necessitates suppliers with advanced synthetic capabilities and stringent quality assurance.

5. Can generic manufacturers readily source lorlatinib intermediates after patent expiry? Upon patent expiry, generic manufacturers will face similar challenges in sourcing high-quality intermediates. They will need to establish their own supply chains, qualify new suppliers, and ensure compliance with all regulatory requirements, which can be a time-consuming and costly process.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/guidances-agreements-guidance-documents/drug-master-files-dmfs [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-european-pharmacopoeia-cep [3] U.S. Food and Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa [4] European Medicines Agency. (n.d.). Falsified medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory-information/overview-drug-approval/falsified-medicines